Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Transcatheter Aortic Valve Replacement | 34 | 2024 | 93 | 14.340 |
Why?
|
Aortic Valve Stenosis | 30 | 2024 | 167 | 11.550 |
Why?
|
Percutaneous Coronary Intervention | 20 | 2024 | 149 | 7.360 |
Why?
|
Atrial Appendage | 10 | 2024 | 26 | 6.090 |
Why?
|
Heart Valve Prosthesis Implantation | 12 | 2024 | 147 | 5.300 |
Why?
|
Treatment Outcome | 77 | 2024 | 5114 | 5.000 |
Why?
|
Heart Valve Prosthesis | 11 | 2023 | 86 | 4.780 |
Why?
|
Myocardial Infarction | 19 | 2024 | 858 | 4.420 |
Why?
|
Aortic Valve | 20 | 2024 | 163 | 4.040 |
Why?
|
ST Elevation Myocardial Infarction | 12 | 2024 | 72 | 3.550 |
Why?
|
Atrial Fibrillation | 12 | 2024 | 793 | 3.290 |
Why?
|
Stroke | 14 | 2024 | 1134 | 3.280 |
Why?
|
Cardiac Catheterization | 9 | 2024 | 238 | 2.930 |
Why?
|
Heart-Assist Devices | 9 | 2023 | 121 | 2.520 |
Why?
|
Embolism | 4 | 2024 | 37 | 2.510 |
Why?
|
Pulmonary Embolism | 4 | 2024 | 170 | 2.370 |
Why?
|
Shock, Cardiogenic | 12 | 2024 | 78 | 2.290 |
Why?
|
Humans | 116 | 2024 | 58810 | 2.210 |
Why?
|
Femoral Artery | 4 | 2022 | 90 | 2.060 |
Why?
|
Thrombosis | 5 | 2023 | 192 | 2.030 |
Why?
|
Risk Factors | 34 | 2024 | 4991 | 2.010 |
Why?
|
Thrombolytic Therapy | 4 | 2024 | 180 | 1.910 |
Why?
|
Peripheral Arterial Disease | 5 | 2020 | 153 | 1.880 |
Why?
|
Foramen Ovale, Patent | 2 | 2024 | 13 | 1.840 |
Why?
|
Endocarditis | 3 | 2022 | 19 | 1.750 |
Why?
|
Pacemaker, Artificial | 4 | 2022 | 40 | 1.750 |
Why?
|
Ischemic Attack, Transient | 3 | 2024 | 91 | 1.720 |
Why?
|
Platelet Aggregation Inhibitors | 6 | 2023 | 247 | 1.710 |
Why?
|
Echocardiography, Transesophageal | 5 | 2024 | 91 | 1.700 |
Why?
|
Anemia | 5 | 2024 | 116 | 1.680 |
Why?
|
Mitral Valve | 3 | 2023 | 101 | 1.680 |
Why?
|
Aortic Valve Insufficiency | 4 | 2023 | 40 | 1.600 |
Why?
|
Coronary Artery Disease | 6 | 2023 | 267 | 1.560 |
Why?
|
Hemorrhage | 6 | 2023 | 277 | 1.540 |
Why?
|
Retrospective Studies | 25 | 2024 | 5959 | 1.420 |
Why?
|
Coronary Occlusion | 2 | 2021 | 7 | 1.420 |
Why?
|
Bioprosthesis | 2 | 2022 | 39 | 1.380 |
Why?
|
Acute Coronary Syndrome | 2 | 2023 | 254 | 1.300 |
Why?
|
Cardiac Surgical Procedures | 3 | 2023 | 243 | 1.290 |
Why?
|
Ventricular Septal Rupture | 2 | 2019 | 2 | 1.280 |
Why?
|
Radiation Exposure | 2 | 2019 | 14 | 1.260 |
Why?
|
Patient Readmission | 9 | 2024 | 413 | 1.220 |
Why?
|
Endovascular Procedures | 5 | 2024 | 550 | 1.210 |
Why?
|
Cardiology | 4 | 2024 | 165 | 1.210 |
Why?
|
Radiography, Interventional | 2 | 2019 | 66 | 1.200 |
Why?
|
Acute Kidney Injury | 5 | 2022 | 125 | 1.190 |
Why?
|
Databases, Factual | 9 | 2024 | 849 | 1.180 |
Why?
|
Radiation Dosage | 2 | 2019 | 122 | 1.180 |
Why?
|
Aged | 34 | 2024 | 13269 | 1.170 |
Why?
|
Thromboembolism | 2 | 2023 | 70 | 1.070 |
Why?
|
Postoperative Complications | 9 | 2024 | 1130 | 1.020 |
Why?
|
Male | 38 | 2024 | 27238 | 1.010 |
Why?
|
Aged, 80 and over | 18 | 2024 | 5062 | 1.000 |
Why?
|
Extracorporeal Membrane Oxygenation | 2 | 2022 | 48 | 0.980 |
Why?
|
Risk Assessment | 11 | 2023 | 1916 | 0.960 |
Why?
|
Hospital Mortality | 10 | 2024 | 867 | 0.920 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2024 | 34 | 0.920 |
Why?
|
Female | 38 | 2024 | 30594 | 0.910 |
Why?
|
Atrial Flutter | 1 | 2024 | 20 | 0.910 |
Why?
|
Vascular System Injuries | 1 | 2024 | 19 | 0.910 |
Why?
|
Radial Artery | 2 | 2022 | 41 | 0.890 |
Why?
|
Migraine Disorders | 1 | 2024 | 45 | 0.880 |
Why?
|
Time Factors | 16 | 2023 | 3559 | 0.870 |
Why?
|
Septal Occluder Device | 2 | 2024 | 11 | 0.860 |
Why?
|
Drug Administration Schedule | 1 | 2023 | 279 | 0.860 |
Why?
|
Social Media | 2 | 2024 | 109 | 0.860 |
Why?
|
Calcinosis | 1 | 2023 | 79 | 0.860 |
Why?
|
Fibrinolytic Agents | 5 | 2024 | 163 | 0.850 |
Why?
|
Coronary Circulation | 2 | 2020 | 48 | 0.820 |
Why?
|
Takotsubo Cardiomyopathy | 1 | 2023 | 65 | 0.820 |
Why?
|
Catheterization, Peripheral | 1 | 2022 | 45 | 0.820 |
Why?
|
Inventions | 1 | 2021 | 3 | 0.800 |
Why?
|
Kidney | 2 | 2023 | 388 | 0.790 |
Why?
|
Off-Label Use | 1 | 2021 | 16 | 0.790 |
Why?
|
Endocarditis, Bacterial | 1 | 2022 | 29 | 0.790 |
Why?
|
Balloon Valvuloplasty | 1 | 2021 | 9 | 0.790 |
Why?
|
Reoperation | 2 | 2022 | 238 | 0.780 |
Why?
|
Lower Extremity | 2 | 2020 | 144 | 0.740 |
Why?
|
Mammary Arteries | 1 | 2020 | 11 | 0.740 |
Why?
|
Hospital Costs | 3 | 2020 | 122 | 0.730 |
Why?
|
Choice Behavior | 1 | 2021 | 76 | 0.730 |
Why?
|
Benchmarking | 1 | 2022 | 135 | 0.720 |
Why?
|
United States | 21 | 2024 | 7496 | 0.710 |
Why?
|
Blood Transfusion | 4 | 2024 | 145 | 0.710 |
Why?
|
Vascular Closure Devices | 1 | 2020 | 1 | 0.710 |
Why?
|
Out-of-Hospital Cardiac Arrest | 1 | 2020 | 42 | 0.700 |
Why?
|
Middle Aged | 22 | 2024 | 16195 | 0.700 |
Why?
|
Drug Costs | 1 | 2020 | 58 | 0.690 |
Why?
|
Intracranial Embolism | 1 | 2020 | 39 | 0.680 |
Why?
|
Cardiovascular Agents | 1 | 2020 | 99 | 0.660 |
Why?
|
Heart Valve Diseases | 1 | 2020 | 86 | 0.650 |
Why?
|
Collateral Circulation | 1 | 2019 | 22 | 0.650 |
Why?
|
Ultrasonography, Interventional | 4 | 2024 | 85 | 0.650 |
Why?
|
Anticoagulants | 5 | 2024 | 485 | 0.640 |
Why?
|
Arteries | 2 | 2020 | 75 | 0.640 |
Why?
|
Contrast Media | 2 | 2024 | 412 | 0.640 |
Why?
|
Vascular Surgical Procedures | 2 | 2024 | 244 | 0.630 |
Why?
|
Heart Septal Defects, Atrial | 1 | 2018 | 8 | 0.630 |
Why?
|
Echocardiography | 6 | 2024 | 454 | 0.620 |
Why?
|
Equipment Failure | 1 | 2018 | 64 | 0.610 |
Why?
|
Diabetes Mellitus | 2 | 2021 | 538 | 0.560 |
Why?
|
Paclitaxel | 1 | 2017 | 87 | 0.560 |
Why?
|
Length of Stay | 6 | 2024 | 775 | 0.530 |
Why?
|
Blood Vessel Prosthesis | 1 | 2017 | 206 | 0.530 |
Why?
|
Skin Diseases, Genetic | 1 | 2015 | 7 | 0.500 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2024 | 664 | 0.500 |
Why?
|
Vascular Malformations | 1 | 2015 | 20 | 0.490 |
Why?
|
Joint Instability | 1 | 2015 | 37 | 0.490 |
Why?
|
Catheters | 3 | 2023 | 65 | 0.470 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2017 | 277 | 0.470 |
Why?
|
Sex Factors | 3 | 2024 | 961 | 0.470 |
Why?
|
Cardiologists | 3 | 2024 | 26 | 0.470 |
Why?
|
Heart Failure | 4 | 2023 | 860 | 0.460 |
Why?
|
Drug-Eluting Stents | 3 | 2023 | 47 | 0.450 |
Why?
|
Chronic Disease | 4 | 2021 | 732 | 0.450 |
Why?
|
Prosthesis Design | 5 | 2021 | 199 | 0.440 |
Why?
|
Microcirculation | 3 | 2024 | 48 | 0.410 |
Why?
|
Recovery of Function | 6 | 2024 | 260 | 0.410 |
Why?
|
Ischemia | 3 | 2024 | 187 | 0.400 |
Why?
|
Cardiovascular Diseases | 2 | 2022 | 826 | 0.400 |
Why?
|
Clinical Protocols | 2 | 2024 | 133 | 0.370 |
Why?
|
Prospective Studies | 6 | 2024 | 3057 | 0.360 |
Why?
|
Inpatients | 5 | 2023 | 294 | 0.350 |
Why?
|
Patient Discharge | 4 | 2021 | 474 | 0.330 |
Why?
|
Secondary Prevention | 2 | 2024 | 150 | 0.330 |
Why?
|
Non-ST Elevated Myocardial Infarction | 2 | 2019 | 32 | 0.320 |
Why?
|
Aspirin | 3 | 2022 | 185 | 0.320 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2020 | 109 | 0.320 |
Why?
|
Practice Patterns, Physicians' | 1 | 2014 | 714 | 0.320 |
Why?
|
Operative Time | 2 | 2019 | 65 | 0.310 |
Why?
|
Equipment Design | 2 | 2020 | 311 | 0.300 |
Why?
|
Registries | 3 | 2020 | 806 | 0.300 |
Why?
|
Multivariate Analysis | 2 | 2020 | 935 | 0.290 |
Why?
|
Intra-Aortic Balloon Pumping | 2 | 2024 | 16 | 0.290 |
Why?
|
Medicare | 3 | 2021 | 608 | 0.270 |
Why?
|
Hospitals | 4 | 2024 | 375 | 0.260 |
Why?
|
Coronary Angiography | 6 | 2023 | 171 | 0.260 |
Why?
|
Prosthesis Failure | 2 | 2022 | 69 | 0.250 |
Why?
|
Mitral Valve Insufficiency | 2 | 2023 | 75 | 0.240 |
Why?
|
Ventricular Function, Left | 3 | 2023 | 259 | 0.240 |
Why?
|
Stroke Volume | 3 | 2023 | 316 | 0.230 |
Why?
|
Surgery, Computer-Assisted | 1 | 2024 | 51 | 0.230 |
Why?
|
Network Meta-Analysis | 1 | 2023 | 16 | 0.230 |
Why?
|
Adenosine Monophosphate | 1 | 2023 | 26 | 0.230 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2023 | 23 | 0.220 |
Why?
|
Limb Salvage | 1 | 2024 | 65 | 0.220 |
Why?
|
Health Resources | 1 | 2024 | 88 | 0.220 |
Why?
|
Observational Studies as Topic | 1 | 2023 | 59 | 0.220 |
Why?
|
Conservative Treatment | 2 | 2022 | 13 | 0.220 |
Why?
|
Mobile Applications | 1 | 2024 | 122 | 0.210 |
Why?
|
Clinical Decision-Making | 1 | 2024 | 137 | 0.210 |
Why?
|
Lactates | 1 | 2022 | 27 | 0.210 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2023 | 149 | 0.210 |
Why?
|
Disease Management | 1 | 2024 | 217 | 0.210 |
Why?
|
Angiography | 4 | 2023 | 148 | 0.210 |
Why?
|
Myocardial Ischemia | 1 | 2022 | 107 | 0.200 |
Why?
|
Thrombectomy | 1 | 2023 | 200 | 0.190 |
Why?
|
Atherectomy, Coronary | 1 | 2021 | 10 | 0.190 |
Why?
|
Patient Selection | 1 | 2024 | 447 | 0.190 |
Why?
|
Prasugrel Hydrochloride | 1 | 2021 | 26 | 0.190 |
Why?
|
Vascular Calcification | 1 | 2021 | 20 | 0.190 |
Why?
|
Survival Rate | 3 | 2024 | 812 | 0.190 |
Why?
|
Internal Mammary-Coronary Artery Anastomosis | 1 | 2020 | 4 | 0.190 |
Why?
|
Coronary Artery Bypass | 2 | 2022 | 274 | 0.190 |
Why?
|
Atherosclerosis | 1 | 2022 | 148 | 0.190 |
Why?
|
Computer Simulation | 1 | 2023 | 446 | 0.190 |
Why?
|
Subclavian Artery | 1 | 2020 | 24 | 0.180 |
Why?
|
Evidence-Based Practice | 1 | 2021 | 81 | 0.180 |
Why?
|
Heart Defects, Congenital | 1 | 2021 | 81 | 0.180 |
Why?
|
Prognosis | 3 | 2020 | 1567 | 0.180 |
Why?
|
Cardiovascular Abnormalities | 1 | 2020 | 32 | 0.180 |
Why?
|
High-Energy Shock Waves | 1 | 2020 | 4 | 0.180 |
Why?
|
Incidence | 3 | 2018 | 1235 | 0.180 |
Why?
|
Surgical Instruments | 1 | 2020 | 42 | 0.180 |
Why?
|
Stents | 2 | 2023 | 430 | 0.180 |
Why?
|
Embolic Protection Devices | 1 | 2019 | 2 | 0.170 |
Why?
|
Factor VIIa | 1 | 2019 | 4 | 0.170 |
Why?
|
Seasons | 1 | 2020 | 138 | 0.170 |
Why?
|
Mechanical Thrombolysis | 1 | 2020 | 35 | 0.170 |
Why?
|
Frailty | 1 | 2022 | 126 | 0.170 |
Why?
|
Punctures | 1 | 2020 | 52 | 0.170 |
Why?
|
Prosthesis Implantation | 1 | 2020 | 30 | 0.170 |
Why?
|
Brachiocephalic Trunk | 1 | 2019 | 15 | 0.170 |
Why?
|
Hemophilia A | 1 | 2019 | 56 | 0.170 |
Why?
|
Cardiac Pacing, Artificial | 1 | 2019 | 34 | 0.170 |
Why?
|
Ventricular Remodeling | 1 | 2020 | 80 | 0.170 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2019 | 19 | 0.170 |
Why?
|
Severity of Illness Index | 3 | 2019 | 1437 | 0.170 |
Why?
|
Upper Extremity | 1 | 2019 | 48 | 0.170 |
Why?
|
Prostheses and Implants | 1 | 2019 | 62 | 0.170 |
Why?
|
Hospitals, Teaching | 1 | 2019 | 102 | 0.170 |
Why?
|
Antibodies, Bispecific | 1 | 2019 | 27 | 0.160 |
Why?
|
Healthcare Disparities | 1 | 2023 | 333 | 0.160 |
Why?
|
Hospitalization | 2 | 2024 | 1264 | 0.160 |
Why?
|
Linear Models | 1 | 2020 | 431 | 0.160 |
Why?
|
Intermittent Claudication | 1 | 2019 | 49 | 0.160 |
Why?
|
Patient Admission | 1 | 2020 | 184 | 0.160 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 289 | 0.160 |
Why?
|
Radiation Injuries | 1 | 2019 | 58 | 0.160 |
Why?
|
Prosthesis-Related Infections | 1 | 2018 | 28 | 0.160 |
Why?
|
Porosity | 1 | 2018 | 37 | 0.160 |
Why?
|
Drug Therapy, Combination | 2 | 2022 | 429 | 0.150 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2019 | 160 | 0.150 |
Why?
|
Prevalence | 2 | 2022 | 1276 | 0.150 |
Why?
|
Lung Diseases | 1 | 2019 | 162 | 0.150 |
Why?
|
Adaptation, Physiological | 1 | 2019 | 115 | 0.150 |
Why?
|
Echocardiography, Doppler, Color | 1 | 2017 | 19 | 0.150 |
Why?
|
Scattering, Radiation | 1 | 2017 | 71 | 0.150 |
Why?
|
Radiation Protection | 1 | 2017 | 23 | 0.150 |
Why?
|
Aortography | 1 | 2017 | 53 | 0.150 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2019 | 219 | 0.150 |
Why?
|
Atherectomy | 1 | 2017 | 9 | 0.150 |
Why?
|
Hospitals, Low-Volume | 1 | 2017 | 23 | 0.140 |
Why?
|
Popliteal Artery | 1 | 2017 | 22 | 0.140 |
Why?
|
Pseudoephedrine | 1 | 2017 | 1 | 0.140 |
Why?
|
Nitroglycerin | 1 | 2017 | 12 | 0.140 |
Why?
|
Metoprolol | 1 | 2017 | 11 | 0.140 |
Why?
|
Hospitals, High-Volume | 1 | 2017 | 38 | 0.140 |
Why?
|
Curriculum | 1 | 2021 | 542 | 0.140 |
Why?
|
Coronary Vasospasm | 1 | 2017 | 11 | 0.140 |
Why?
|
Computed Tomography Angiography | 1 | 2017 | 109 | 0.140 |
Why?
|
Angioplasty, Balloon | 1 | 2017 | 56 | 0.140 |
Why?
|
Vascular Diseases | 1 | 2017 | 69 | 0.140 |
Why?
|
Logistic Models | 1 | 2019 | 1268 | 0.130 |
Why?
|
Patient Safety | 1 | 2017 | 238 | 0.120 |
Why?
|
Patient Acceptance of Health Care | 1 | 2019 | 445 | 0.120 |
Why?
|
Ticlopidine | 1 | 2014 | 65 | 0.120 |
Why?
|
Cohort Studies | 1 | 2019 | 2434 | 0.110 |
Why?
|
Asthma | 1 | 2017 | 414 | 0.100 |
Why?
|
Microbubbles | 2 | 2024 | 2 | 0.100 |
Why?
|
Hemoglobins | 2 | 2023 | 139 | 0.100 |
Why?
|
Electrocardiography | 3 | 2020 | 518 | 0.100 |
Why?
|
Hemodynamics | 2 | 2019 | 214 | 0.070 |
Why?
|
Odds Ratio | 2 | 2021 | 791 | 0.070 |
Why?
|
Access to Information | 1 | 2024 | 30 | 0.060 |
Why?
|
Diffusion of Innovation | 1 | 2024 | 55 | 0.060 |
Why?
|
Computer-Assisted Instruction | 1 | 2024 | 75 | 0.060 |
Why?
|
Education, Medical, Continuing | 1 | 2024 | 101 | 0.060 |
Why?
|
Embryonic and Fetal Development | 1 | 2003 | 47 | 0.060 |
Why?
|
Information Dissemination | 1 | 2024 | 113 | 0.060 |
Why?
|
Lactic Acid | 1 | 2023 | 70 | 0.060 |
Why?
|
Erythrocyte Transfusion | 1 | 2023 | 74 | 0.050 |
Why?
|
Pulmonary Artery | 1 | 2023 | 84 | 0.050 |
Why?
|
Ankle Brachial Index | 1 | 2022 | 14 | 0.050 |
Why?
|
Bundle-Branch Block | 1 | 2022 | 14 | 0.050 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2002 | 34 | 0.050 |
Why?
|
Acetaminophen | 1 | 2002 | 50 | 0.050 |
Why?
|
Recurrence | 1 | 2023 | 569 | 0.050 |
Why?
|
Nutrition Surveys | 1 | 2022 | 152 | 0.050 |
Why?
|
Warfarin | 1 | 2022 | 108 | 0.050 |
Why?
|
Feasibility Studies | 1 | 2023 | 509 | 0.050 |
Why?
|
Aftercare | 1 | 2021 | 66 | 0.050 |
Why?
|
Societies, Medical | 1 | 2023 | 331 | 0.050 |
Why?
|
Nerve Tissue Proteins | 1 | 2003 | 419 | 0.050 |
Why?
|
Friends | 1 | 2020 | 29 | 0.040 |
Why?
|
Postoperative Care | 1 | 2021 | 111 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2020 | 2010 | 0.040 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2020 | 23 | 0.040 |
Why?
|
Tomography, Optical Coherence | 1 | 2022 | 197 | 0.040 |
Why?
|
Adult | 3 | 2022 | 15608 | 0.040 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2003 | 629 | 0.040 |
Why?
|
Constriction, Pathologic | 1 | 2019 | 95 | 0.040 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 95 | 0.040 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2024 | 742 | 0.040 |
Why?
|
Vascular Patency | 1 | 2019 | 133 | 0.040 |
Why?
|
Fluorocarbons | 1 | 2019 | 30 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2019 | 133 | 0.040 |
Why?
|
Forecasting | 1 | 2019 | 218 | 0.040 |
Why?
|
Heart Ventricles | 1 | 2020 | 247 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 350 | 0.040 |
Why?
|
Heart | 1 | 2020 | 274 | 0.040 |
Why?
|
Emergencies | 1 | 2018 | 115 | 0.040 |
Why?
|
Heart Diseases | 1 | 2019 | 209 | 0.030 |
Why?
|
Vasodilator Agents | 1 | 2017 | 58 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 900 | 0.030 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2017 | 89 | 0.030 |
Why?
|
Bronchodilator Agents | 1 | 2017 | 94 | 0.030 |
Why?
|
Skilled Nursing Facilities | 1 | 2017 | 84 | 0.030 |
Why?
|
Transcription Factors | 1 | 2003 | 1448 | 0.030 |
Why?
|
Brain | 1 | 2003 | 1464 | 0.030 |
Why?
|
Comorbidity | 1 | 2017 | 1095 | 0.030 |
Why?
|
Emergency Service, Hospital | 1 | 2021 | 1008 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2018 | 2320 | 0.030 |
Why?
|
Adolescent | 1 | 2020 | 5857 | 0.020 |
Why?
|
PAX6 Transcription Factor | 1 | 2003 | 4 | 0.010 |
Why?
|
Paired Box Transcription Factors | 1 | 2003 | 17 | 0.010 |
Why?
|
Octamer Transcription Factor-3 | 1 | 2003 | 15 | 0.010 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 2003 | 23 | 0.010 |
Why?
|
Organ Culture Techniques | 1 | 2003 | 71 | 0.010 |
Why?
|
Blotting, Northern | 1 | 2003 | 151 | 0.010 |
Why?
|
Eye Proteins | 1 | 2003 | 73 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 2003 | 218 | 0.010 |
Why?
|
Gestational Age | 1 | 2003 | 178 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2003 | 381 | 0.010 |
Why?
|
Embryo, Mammalian | 1 | 2003 | 161 | 0.010 |
Why?
|
X-Ray Diffraction | 1 | 2002 | 56 | 0.010 |
Why?
|
Crystallization | 1 | 2002 | 97 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 521 | 0.010 |
Why?
|
Blotting, Western | 1 | 2003 | 590 | 0.010 |
Why?
|
Homeodomain Proteins | 1 | 2003 | 254 | 0.010 |
Why?
|
Repressor Proteins | 1 | 2003 | 332 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2003 | 1974 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2003 | 1967 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2003 | 1462 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2003 | 1125 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2003 | 3139 | 0.010 |
Why?
|
Mice | 1 | 2003 | 10140 | 0.010 |
Why?
|
Animals | 1 | 2003 | 19395 | 0.000 |
Why?
|